2019
DOI: 10.1016/j.cell.2019.10.007
|View full text |Cite|
|
Sign up to set email alerts
|

Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma

Abstract: Highlights d Integrated proteogenomic characterization in 103 ccRCC cases d Delineation of chromosomal translocation events leading to chromosome 3p loss d Tumor-specific proteomic/phosphoproteomic alterations unrevealed by mRNA analysis d Immune-based subtypes of ccRCC defined by mRNA, proteome, and phosphoproteome

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

19
415
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
6
2

Relationship

3
5

Authors

Journals

citations
Cited by 518 publications
(468 citation statements)
references
References 190 publications
(239 reference statements)
19
415
0
Order By: Relevance
“…1 E). We also analyzed proteomics data on clear cell renal cancer from the National Cancer Institute (NCI)–sponsored Clinical Proteomic Tumor Analysis Consortium, which was recently reported using the UALCAN analysis portal (Chen et al, 2019; Clark et al, 2019). These data clearly demonstrate reduced PRDM16 protein in RCC and therefore validate both our immunoblot and immunohistochemistry analyses (Fig.…”
Section: Resultsmentioning
confidence: 99%
“…1 E). We also analyzed proteomics data on clear cell renal cancer from the National Cancer Institute (NCI)–sponsored Clinical Proteomic Tumor Analysis Consortium, which was recently reported using the UALCAN analysis portal (Chen et al, 2019; Clark et al, 2019). These data clearly demonstrate reduced PRDM16 protein in RCC and therefore validate both our immunoblot and immunohistochemistry analyses (Fig.…”
Section: Resultsmentioning
confidence: 99%
“…Renal cell carcinoma (RCC), one of the top ten most commonly diagnosed cancers worldwide, is dominated by the clear cell histological subtype, which makes up 75% of all RCC cases [1]. To…”
Section: Ccrcc Data Descriptionmentioning
confidence: 99%
“…In addition, through ProTrack users can efficiently generate visual heatmaps of customized combinations of multi-omic data from CPTAC and perform an initial query of such associations. In this paper, we focus on introducing ProTrack for the CPTAC clear cell renal cell carcinoma (ccRCC) study [1], importantly similar tools for CPTAC proteogenomic studies of other cancer types, will be made available as and when the corresponding data is released by the consortium or upon publication.…”
mentioning
confidence: 99%
“…We first wanted to know how these measurements relate to each other to determine the extent that one measurement can stand as a proxy for overall LINE-1 "activity." We reanalyzed data from the CPTAC project to quantify LINE-1 mRNA, ORF1p (L1RE1) and ORF1p S18, S27, S33 and T203 phosphorylation in 5 cancer types: breast (n=94; (Krug et al, 2020) ), ovarian (n=97; (McDermott et al, 2020) ), colon (n=93) (Vasaikar et al, 2019) , clear cell kidney (n=106) (Clark et al, 2019) and endometrial (n=88) (Dou et al, 2020) . We also used the Mobile Element Locator Tool (MELT) to quantify somatic LINE-1 insertions in kidney and endometrial tumors, where matched tumor and whole blood WGS was available.…”
Section: Quantifications Of Line-1 Expression Orf1p Phosphorylationmentioning
confidence: 99%
“…Transcriptomic and genomic data for CPTAC 3 (endometrial and kidney cancers) can be found in the Genomic Data Commons ( https://gdc.cancer.gov/ ). Additionally data for each cancer type can be found in the corresponding publication: colon (Vasaikar et al, 2019), breast (Krug et al, 2020), ovarian (McDermott et al, 2020), endometrial (Dou et al, 2020), and kidney (Clark et al, 2019). L1EM code can be found at https://github.com/FenyoLab/L1EM .…”
Section: Data and Code Availabilitymentioning
confidence: 99%